Guided by nature The Power of
Remyelination
READ MORE
Rewinding the damage Restoring the
myelin sheath
READ MORE
Decades of expertise Meet the minds behind
Rewind Therapeutics
READ MORE

Restoring the myelin sheath

Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. A common feature of these illnesses is the loss of the natural myelin sheath, a cover protecting and nurturing the nerves. Repairing or re-installing this sheath (i.e., remyelination) is a crucial factor for halting or even curing these diseases. Rewind´s team has extensive research and development expertise and a strong patent estate for developing novel remyelination therapeutics. Based in Leuven, Belgium, Rewind is backed by top-tier life science investors such as Boehringer Ingelheim Venture Fund, M. Ventures, Axxam, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.

Developing
novel remyelination
therapeutics

Investors & Partners

This website uses cookies to ensure you get the best experience on our website. Get more details by clicking on the Button below.